Objective: We aimed to assess the incidence, management, and visual outcome of acute endophthalmitis in patients following intravitreal bevacizumab injection in a tertiary care setup. It was a prospective and single-center database study.
Patients And Methods: Patients receiving intravitreal bevacizumab injections for various retinal vascular diseases from January 2019 to September 2020.